Patents by Inventor Nicholas Robert Perl

Nicholas Robert Perl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterobicyclic amides as inhibitors of CD38
    Patent number: 11987584
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Grant
    Filed: December 5, 2022
    Date of Patent: May 21, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY
    Publication number: 20240101540
    Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: July 28, 2023
    Publication date: March 28, 2024
    Inventors: Nicholas Robert Perl, Kevin Wayne Kuntz, Jennifer Downing
  • TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY
    Publication number: 20240051946
    Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 15, 2024
    Inventors: Nicholas Robert Perl, Kevin Wayne Kuntz
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20240034728
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: May 12, 2023
    Publication date: February 1, 2024
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
    Publication number: 20230381153
    Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.
    Type: Application
    Filed: May 12, 2023
    Publication date: November 30, 2023
    Inventors: Joon Jung, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Nicholas Robert Perl, Peter Germano, Maria D. Ribadeneira, Kim Tang
  • HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38
    Publication number: 20230312586
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 5, 2023
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • SOLID FORMS OF A PARP14 INHIBITOR
    Publication number: 20230303542
    Abstract: The present invention relates to solid forms of the poly(ADP-ribose) polymerase 14 (PARP14) inhibitor 7-((1-acetylpiperidin-4-yl)methoxy)-5-fluoro-2-(((tetrahydro-2H-pyran-4-yl)thio)methyl)quinazolin-4(3H)-one, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: February 8, 2023
    Publication date: September 28, 2023
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz, Nicholas Robert Perl, John Alphons Kremers, Zheng Jane Li, Pengyuan Chen
  • Pyridazinones as PARP7 inhibtors
    Patent number: 11691969
    Abstract: The present invention relates to pyridazinones and related compounds having Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 4, 2023
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • Treatment of CNS diseases with sGC stimulators
    Patent number: 11690828
    Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: July 4, 2023
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: Joon Jung, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Nicholas Robert Perl, Peter Germano, Maria D. Ribadeneira, Kim Tang
  • sGC STIMULATORS
    Publication number: 20230106002
    Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 6, 2023
    Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Lei Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
  • Heterobicyclic amides as inhibitors of CD38
    Patent number: 11535621
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: December 27, 2022
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • sGC stimulators
    Patent number: 11207323
    Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 28, 2021
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Lei Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
  • PYRAZOLE DERIVATIVES AS SGC STIMULATORS
    Publication number: 20210221793
    Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Application
    Filed: January 7, 2021
    Publication date: July 22, 2021
    Inventors: Timothy Claude Barden, James Edward Sheppeck, Glen Robert Rennie, Paul Allan Renhowe, Nicholas Robert Perl, Takashi Nakai, Ara Mermerian, Thomas Wai-Ho Lee, Joon Jung, Lei Jia, Karthik Iyer, Rajesh R. Iyengar, G-Yoon Jamie Im
  • sGC STIMULATORS
    Publication number: 20210214364
    Abstract: The present patent application discloses at least the compounds according to Formula l shown below, or pharmaceutically acceptable salts thereof, wherein ringjB,n, JD, J,0, X, X1, J, RC, and W are as defined herein. These compounds are useful as simulators of soluble sGC.
    Type: Application
    Filed: December 15, 2020
    Publication date: July 15, 2021
    Inventors: Paul Allan Renhowe, James Edward Sheppeck, Takashi Nakai, Karthik Iyer, Nicholas Robert Perl, Glen Robert Rennie, Mark G. Currie, Kimberly Kafadar Long, George Todd Milne, Rajesh R. Iyengar
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20210130342
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: October 29, 2020
    Publication date: May 6, 2021
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38
    Publication number: 20210032251
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • sGC STIMULATORS
    Publication number: 20200316065
    Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Application
    Filed: March 13, 2020
    Publication date: October 8, 2020
    Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Lei Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
  • sGC stimulators
    Patent number: 10639308
    Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: May 5, 2020
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Lei Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
  • sGC stimulators
    Patent number: 10517874
    Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: December 31, 2019
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie, James Jia
  • TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
    Publication number: 20190343813
    Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.
    Type: Application
    Filed: November 7, 2017
    Publication date: November 14, 2019
    Applicant: Cyclerion Therapeutics, Inc.
    Inventors: Joon Jung, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Nicholas Robert Perl, Peter Germano, Maria D. Ribadeneira, Kim Tang